Mustang Bio (MBIO) News Today $1.64 +0.12 (+7.89%) As of 01:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBIO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Mustang Bio Inc.July 25, 2025 | barrons.comTalisker Receives Assay Results from 1105 Level Lateral Development at the Mustang MineJuly 24, 2025 | globenewswire.comMBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy - NasdaqJuly 10, 2025 | nasdaq.comMustang Bio Stock Jumps 180% After FDA Grants Orphan Drug Status to Brain Cancer DrugJuly 10, 2025 | msn.comMustang Bio Inc News (MBIO) - Investing.comJuly 9, 2025 | investing.comDow Dips 1%; Mustang Bio Shares Spike HigherJuly 7, 2025 | benzinga.comMustang Bio stock soars after FDA grants orphan drug designationJuly 7, 2025 | investing.comMustang Bio rises after FDA orphan drug status for MB-101July 7, 2025 | msn.comMustang Bio Shares Surge After FDA Grants Orphan Drug StatusJuly 7, 2025 | msn.comMustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and GlioblastomaJuly 7, 2025 | globenewswire.comMustang Bio, Inc. (MBIO) - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comMustang Bio treatment of malignant glioma granted orphan designationJuly 2, 2025 | msn.comMBIO Mustang Bio, Inc. - Seeking AlphaJune 25, 2025 | seekingalpha.comMustang Bio meets Nasdaq’s equity listing requirementsMarch 7, 2025 | investing.comMustang Bio Regains Nasdaq Compliance, Secures Position For Cell Therapy AdvancementsMarch 7, 2025 | nasdaq.comMustang Bio regains compliance with Nasdaq requirementMarch 5, 2025 | markets.businessinsider.comMustang Bio Regains Compliance with Nasdaq Capital Market RequirementMarch 5, 2025 | globenewswire.comMustang Bio exits Worcester facility, sells assets to AbbVieMarch 1, 2025 | uk.investing.comMustang Bio, Inc.: Mustang Bio Announces Sale of Fixed Assets and Exit of FacilityFebruary 28, 2025 | finanznachrichten.deMustang Bio to Exit Lease of Worcester, Mass. Manufacturing FacilityFebruary 27, 2025 | marketwatch.comMustang Bio exits lease for Massachusetts facility, divests equipmentFebruary 27, 2025 | markets.businessinsider.comMustang Bio stock plunges 29% on lease termination newsFebruary 27, 2025 | msn.comMustang Bio Announces Sale of Fixed Assets and Exit of FacilityFebruary 27, 2025 | globenewswire.comMustang Bio sells assets and ends lease with AbbVieFebruary 13, 2025 | msn.comMustang Bio stock plunges to 52-week low of $2.6 amid sharp declineFebruary 13, 2025 | msn.comMustang Bio regains compliance with NasdaqFebruary 11, 2025 | markets.businessinsider.comMustang Bio Regains Compliance with Nasdaq Minimum Bid Price RequirementFebruary 11, 2025 | globenewswire.comMustang Bio Announces Closing of $8 Million Public OfferingFebruary 10, 2025 | globenewswire.comMustang Bio Announces Pricing of $8 Million Public OfferingFebruary 7, 2025 | markets.businessinsider.comMustang Bio prices 2.66M shares at $3.01 in public offeringFebruary 7, 2025 | markets.businessinsider.comMustang Bio Prices Public Offering Of 2.65 Mln At $3.01/shr; Stock Down In Pre-marketFebruary 7, 2025 | markets.businessinsider.comMustang Bio stock plunges to 52-week low of $4January 22, 2025 | msn.comMustang Bio files to sell common stock and warrants, no amount givenJanuary 16, 2025 | markets.businessinsider.comMustang Bio trading halted, news pendingJanuary 16, 2025 | markets.businessinsider.comMustang Bio Sets 1-for-50 Reverse Stock SplitJanuary 15, 2025 | markets.businessinsider.comMustang Bio announces 1-for-50 reverse stock splitJanuary 14, 2025 | markets.businessinsider.comMustang Bio Lauds New Stock SplitJanuary 14, 2025 | baystreet.caMustang Bio Announces Reverse Stock SplitJanuary 14, 2025 | globenewswire.comCarmell, Mustang Bio, Revelation Biosciences Dominate Retail Biotech Talk As 2025 Kicks OffJanuary 3, 2025 | msn.comMustang Bio Interim CFO James Murphy ResignsNovember 16, 2024 | markets.businessinsider.comMustang Bio's Interim CFO Resigns After 10 MonthsNovember 15, 2024 | marketwatch.comMustang Bio Faces Nasdaq Delisting and Leadership ChangesNovember 15, 2024 | markets.businessinsider.comMustang Bio, Inc.: Mustang Bio Receives Positive Listing Determination from NasdaqNovember 12, 2024 | finanznachrichten.deMustang Bio Receives Positive Listing Determination from NasdaqNovember 12, 2024 | globenewswire.comMustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant GliomaNovember 7, 2024 | globenewswire.comMustang Bio Secures $4M through Strategic Warrant AgreementOctober 25, 2024 | markets.businessinsider.comMustang Bio Announces Exercise of Warrants for $4 Million Gross ProceedsOctober 24, 2024 | globenewswire.comMustang Bio treatment of malignant glioma granted FDA orphan statusOctober 23, 2024 | markets.businessinsider.comMustang Bio (NASDAQ:MBIO) Stock, Short Interest ReportSeptember 28, 2024 | benzinga.comMustang Bio (NASDAQ:MBIO) Stock Quotes, Forecast and News SummarySeptember 28, 2024 | benzinga.com Get Mustang Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address MBIO Media Mentions By Week MBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MBIO News Sentiment▼-1.000.37▲Average Medical News Sentiment MBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MBIO Articles This Week▼11▲MBIO Articles Average Week Get Mustang Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies FBLG News RNTX News NNVC News EQ News PMN News BDRX News LGVN News QTTB News NAII News RLYB News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MBIO) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredGold Hit $3,500. Here’s What’s Next…Gold just smashed through $3,500—and some experts believe that’s only the beginning. With big banks like Goldm...Reagan Gold Group | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mustang Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mustang Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
